163O Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)

Published 2022 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 33, Issue -, Pages S196-S197

Publisher

Elsevier BV

Online

2022-05-05

DOI

10.1016/j.annonc.2022.03.182

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Create your own webinar